Friday, September 23, 2005 10:25:52 PM
NEW HAVEN, Conn. and TOKYO, Sept. 21 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into a pharmacogenomic research collaboration with Otsuka Pharmaceutical Co., Ltd. Under the terms of the agreement, Genaissance will apply its HAP(TM) Technology with the goal of identifying genetic markers related to drug response. Genaissance and Otsuka will be co-owners of the intellectual property that results from the collaboration and both companies will be eligible to receive royalties on revenues generated from diagnostic products resulting from the collaboration.
Peace, Blessings & Boat Drinks, Easy
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • Oct 15, 2024 8:21 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
CBD Life Sciences, Inc. Announces Strategic MOU with U.S. Armed Forces for Groundbreaking Mushroom Supplement • CBDL • Oct 15, 2024 8:00 AM
HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi • HLYK • Oct 15, 2024 8:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM